APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants

Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15(9):501–18.

CAS  Article  Google Scholar 

Li Z, Shue F, Zhao N, Shinohara M, Bu G. APOE2: protective mechanism and therapeutic implications for Alzheimer's disease. Mol Neurodegener. 2020;15(1):63.

CAS  Article  Google Scholar 

Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. Mol Neurodegener. 2020;15(1):40.

Article  Google Scholar 

Martens YA, Zhao N, Liu CC, Kanekiyo T, Yang AJ, Goate AM, et al. ApoE Cascade hypothesis in the pathogenesis of Alzheimer's disease and related dementias. Neuron. 2022;110(8):1304–17.

CAS  Article  Google Scholar 

Li Y, Macyczko JR, Liu CC, Bu G. ApoE4 reduction: an emerging and promising therapeutic strategy for Alzheimer's disease. Neurobiol Aging. 2022;115:20–8.

CAS  Article  Google Scholar 

Shinohara M, Kanekiyo T, Yang L, Linthicum D, Fu Y, Price L, Frisch-Daiello JL, Han X, Fryer JD, Bu G. APOE2 eases cognitive decline during Aging: Clinical and preclinical evaluations. Ann Neurol. 2016;79(5):758-74. https://doi.org/10.1002/ana.24628. Epub 2016 Mar 29.

Shinohara M, Kanekiyo T, Tachibana M, Kurti A, Shinohara M, Fu Y, Zhao J, Han X, Sullivan PM, Rebeck GW, et al. APOE2 is associated with longevity independent of Alzheimer's disease. Elife. 2020;9:e62199. https://doi.org/10.7554/eLife.62199.

Wang T, Huynh K, Giles C, Mellett NA, Duong T, Nguyen A, Lim WLF, Smith AA, Olshansky G, Cadby G, et al. APOE ε2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies. Alzheimers Dement. 2022. https://doi.org/10.1002/alz.12538. Online ahead of print

Zhao N, Ren Y, Yamazaki Y, Qiao W, Li F, Felton LM, et al. Alzheimer's risk factors age, APOE genotype, and sex drive distinct molecular pathways. Neuron. 2020;106(5):727–742.e726.

CAS  Article  Google Scholar 

Arboleda-Velasquez JF, Lopera F, O'Hare M, Delgado-Tirado S, Marino C, Chmielewska N, et al. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25(11):1680–3.

CAS  Article  Google Scholar 

Medway CW, Abdul-Hay S, Mims T, Ma L, Bisceglio G, Zou F, Pankratz S, Sando SB, Aasly JO, Barcikowska M, et al. ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease. Mol Neurodegener. 2014;9:11. https://doi.org/10.1186/1750-1326-9-11.

Liu CC, Murray ME, Li X, Zhao N, Wang N, Heckman MG, et al. APOE3-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Sci Transl Med. 2021;13(613):eabc9375.

CAS  Article  Google Scholar 

Raulin AC, Martens YA, Bu G. Lipoproteins in the central nervous system: from biology to pathobiology. Annu Rev Biochem. 2022;91:731–59.

Article  Google Scholar 

Le Guen Y, Belloy ME, Grenier-Boley B, de Rojas I, Castillo-Morales A, Jansen I, Nicolas A, Bellenguez C, Dalmasso C, Küçükali F, et al. Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurol. 2022;79(7):652-63. https://doi.org/10.1001/jamaneurol.2022.1166.

Chen J, Li Q, Wang J. Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc Natl Acad Sci U S A. 2011;108(36):14813–8.

CAS  Article  Google Scholar 

留言 (0)

沒有登入
gif